MEREO BIOPHARMA GROUP PLC Nonderivative Financial Liabilities Undiscounted Cash Flows
MEREO BIOPHARMA GROUP PLC (MREO) had Nonderivative Financial Liabilities Undiscounted Cash Flows of GBP 5.59 million as of 2020-12-31, per its 20-F filed 2021-03-31.
Discontinued › Notes
ifrs-full:NonderivativeFinancialLiabilitiesUndiscountedCashFlows · last filed 2021-03-31
- 2020-12-31: Nonderivative Financial Liabilities Undiscounted Cash Flows 5.59M GBP.
- 2019-12-31: Nonderivative Financial Liabilities Undiscounted Cash Flows 49.67M GBP.
- 2018-12-31: Nonderivative Financial Liabilities Undiscounted Cash Flows 31.20M GBP; Nonderivative Financial Liabilities Undiscounted Cash Flows as first filed 26.71M GBP.
| Period end | Nonderivative Financial Liabilities Undiscounted Cash Flows | Nonderivative Financial Liabilities Undiscounted Cash Flows as first filed |
|---|---|---|
| 2020-12-31 | 5.59M GBP 20-F · filed 2021-03-31 | |
| 2019-12-31 | 49.67M GBP 20-F · filed 2020-06-15 | |
| 2018-12-31 | 31.20M GBP 20-F · filed 2020-06-15 | 26.71M GBP 20-F/A · filed 2019-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |